Disease-Modifying Therapy for Parkinson's Disease Hideki Shimura 1 , Nobutaka Hattori 2 1Department of Neurology, Juntendo University Urayasu Hospital 2Department of Neurology, Juntendo University School of Medicine Keyword: パーキンソン病 , 疾患修飾薬 , αシヌクレイン , 遺伝子治療 , 細胞移植治療 , Parkinson's disease , disease-modifying drugs , α-synuclein , gene therapy , cell transplantation therapy pp.159-165
Published Date 2017/2/1
DOI https://doi.org/10.11477/mf.1416200656
  • Abstract
  • Look Inside
  • Reference


Currently, treatment of Parkinson's disease aims at alleviating its symptoms. However development of disease-modifying drugs has been a remarkable advancement in recent years. Furthermore, clinical trials of immunotherapy against α-synuclein, a protein involved in the pathogenesis of and lesion expansion in Parkinson's disease, have been initiated. Here, the disease-modifying treatment for patients with Parkinson's disease including the current α-synuclein immunotherapy, gene therapy, protein injection therapy, and cell transplantation therapy, has been reviewed.

Copyright © 2017, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院